Sprint Fidelis
-
Hawkins exit may show Medtronic’s need for bold leader/big deals
When Medtronic Inc. (NYSE:MDT) CEO Art Collins retired in 2007, there were at least two top candidates vying to replace him. One was Michael DeMane, the brash president of Medtronic’s spine business whose aggressive pursuit of growth invited legal and regulatory scrutiny. The other was chief operating officer Bill Hawkins, a steady, stabilizing presence within Medtronic’s senior leadership team.
-
Medtronic’s Sprint Fidelis settlement leaves some patients out in the cold
From a strictly legal sense, Medtronic Inc. (NYSE:MDT) has closed the book on its Sprint Fidelis debacle. The Fridley, Minnesota, company won a landmark victory in the U.S. Supreme Court that effectively shields medical device makers from liability of Food and Drug Administration-approved devices. And in October, Medtronic said it would pay $268 million to settle all lawsuits relating to its Sprint Fidelis leads. But about 260,000 Sprint Fidelis leads have been implanted in patients in the United States, with 143,000 still active.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Medtronic to settle Sprint Fidelis lawsuits for $268 million
Medtronic Inc. (NYSE: MDT) said Thursday it will pay $260 million to settle all U.S. lawsuits relating to its faulty Sprint Fidelis defibrillator leads. In exchange, plaintiffs’ lawyers agreed to dismiss related litigation nationwide.
-
Appeal plaintiffs fail to show Medtronic hid Sprint Fidelis problems
The U.S. Appeals Court for the Eighth District shot down the appeal of a ruling dismissing a shareholders lawsuit against Medtronic Inc. (NYSE:MDT), saying the plaintiffs failed to prove the company deliberately concealed problems with its Sprint Fidelis leads.
-
Medtronic expertise (& family connections) guide Cameron Health
In mid-May, Cameron Health Inc. struck media gold when the New York Times and the New England Journal of Medicine both gave prominent coverage to the company’s efforts to develop the medical device industry’s first subcutaneous implantable cardioverter defibrillator (ICD). Not bad for a relatively unknown startup in San Clemente, California. But a week earlier, Cameron struck managerial gold when it hired Warren Watson.
-
Medtronic Inc., startups eye lead-less heart devices
Medtronic Inc. (NYSE:MDT) is quietly working on plans to develop a pacemaker that can deliver electricity to the heart without wires.
The company, based in Fridley, Minnesota, confirmed to MedCity News begin_of_the_skype_highlighting end_of_the_skype_highlighting that it’s building a leadless pacemaker but offered no further details on the device, which reportedly can be implanted directly into the right ventricle.
-
New appointment of FDA official unsettles medical device industry
Since he assumed his post in January, Dr. Jeffrey Shuren, the top Food and Drug […]
-
Devices & Diagnostics, MedCity Influencers
Medtronic hit with lawsuits over stents, defibrillators
Medtronic Inc. (NYSE:MDT) is fielding a pair of lawsuits, one accusing it of product liability […]
-
A note on the Med Tech Investment conference in Minneapolis
As a journalist, I’m frequently beset with impulsive self-righteousness. Which is why I jumped the […]
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Sprint Fidelis lead woes continue to haunt Medtronic, industry as FDA takes notice
The Food and Drug Administration, urged by Congress, has already taken a harder line on 510(k)s. Which makes it only a matter of time before the agency, wary of another Sprint Fidelis debacle, sets its sights on PMA supplements.